Consensus on Control of Risky Nonvariceal Upper Gastrointestinal Bleeding in Taiwan with National Health Insurance

Bor-Shyang Sheu, Chun-Ying Wu, Ming-Shiang Wu, Cheng-Tang Chiu, Chun-Che Lin, Ping-I Hsu, Hsiu-Chi Cheng, Teng-Yu Lee, Hsiu-Po Wang, and Jaw-Town Lin

1 Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2 Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3 Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
4 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
5 Gastroenterology Endoscopy Center, Chang Gung Memorial Hospital, Linko, Taiwan
6 Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
7 Department of Internal Medicine, Tainan Hospital, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
8 School of Medicine, Fu Jen Catholic University, No. 510 Zhongzheng Road, Xinzhuang District, New Taipei City 24205, Taiwan

Correspondence should be addressed to Jaw-Town Lin; jawtown@gmail.com

Received 13 June 2014; Accepted 1 August 2014; Published 14 August 2014

Copyright © 2014 Bor-Shyang Sheu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aims. To compose upper gastrointestinal bleeding (UGIB) consensus from a nationwide scale to improve the control of UGIB, especially for the high-risk comorbidity group.

Methods. The steering committee defined the consensus scope to cover preendoscopy, endoscopy, postendoscopy, and overview from Taiwan National Health Insurance Research Database (NHIRD) assessments for UGIB. The expert group comprised thirty-two Taiwan experts of UGIB to conduct the consensus conference by a modified Delphi process through two separate iterations to modify the draft statements and to vote anonymously to reach consensus with an agreement ≥80% for each statement and to set the recommendation grade.

Results. The consensus included 17 statements to highlight that patients with comorbidities, including liver cirrhosis, end-stage renal disease, probable chronic obstructive pulmonary disease, and diabetes, are at high risk of peptic ulcer bleeding and rebleeding. Special considerations are recommended for such risky patients, including raising hematocrit to 30% in uremia or acute myocardial infarction, aggressive acid secretory control in high Rockall scores, monitoring delayed rebleeding in uremia or cirrhosis, considering cyclooxygenase-2 inhibitors plus PPI for pain control, and early resumption of antplatelets plus PPI in coronary artery disease or stroke.

Conclusions. The consensus comprises recommendations to improve care of UGIB, especially for high-risk comorbidities.

1. Introduction

Upper gastrointestinal bleeding (UGIB) is a highly prevalent and potentially fatal condition worldwide [1, 2]. The incidence of UGIB has an increasing trend in elderly people with comorbid illnesses and in users of nonsteroid anti-inflammatory drugs (NSAIDs) [1, 2]. The recommendations from previous UGIB guidelines and reviews have resulted in improvements in patients care and outcomes [3–5]. The international consensus recommendations on the management of patients with nonvariceal UGIB were updated in 2010 with a substantial expansion [1]. Due to concerns about Asia-Pacific regional differences in patient characteristics and healthcare systems as compared to developed Western countries, some
specific strategies have been revised [2]. However, there remains evident diversity in the availability of medications and endoscopy facilities within the Asia-Pacific region.

In Taiwan, endoscopy and the therapeutic modalities are readily available on a nationwide scale. Moreover, the National Health Insurance program, which covers more than 99% of the entire population of Taiwan, provides full support for medication and endoscopy for UGIB. Therefore, there is a need to refresh the current consensus for patient care of peptic ulcer bleeding. Although some recommendations in this consensus are based on local data extracted from the National Health Insurance program, these recommendations address many important issues, for example, comorbidity, also emerging in other countries [6]. Because patients are now older and sicker than before, the consensus statements can be applied in general to improve evolution in health care due to the aging population worldwide.

Owing to the National Health Insurance Research Database (NHIRD) which covers more than 23 million residents over more than 15 years, the current consensus has provided strong evidence of its validity in a nationwide cohort setting for UGIB. To collect recommendations from a nationwide scale to improve the outcomes of UGIB, especially to improve the care for the high-risk group, is a novel project.

2. Methods

2.1. Scope Setting and Preparation Structure of Consensus by a Steering Committee. To establish the expert consensus of UGIB in Taiwan, the steering committee was initiated by J. T. Lin, chaired by B. S. Sheu, and cochaired by C. Y. Wu along with seven other opinion leaders from the Gastroenterological Society of Taiwan (M. S. Wu, C. T. Chiu, C. J. Lin, P. I. Hsu, H. C. Cheng, T. Y. Lee, and H. P. Wang). The steering committee defined the scope sessions of the consensus, searched for and reviewed the literature, formulated the draft statements, and defined the statement evidence level.

2.2. Literature Search and Review to Address the Draft Statements with Evidence Level Grading. The literature searches included Medline, Embase, the Cochrane Central Register of Controlled Trial, and ISI Web of Knowledge, with manual searches of bibliographies of key articles and proceedings of abstracts of major gastroenterology conferences held over the past 7 years. The keywords used in the search included gastrointestinal bleeding, peptic ulcer, proton pump inhibitor, upper gastrointestinal endoscopy, rebleeding, and mortality.

The members of the steering committee summarized the findings into the four scope sessions of this consensus: the first three sessions were ranked in order by patient-centric time-framed allocations from preendoscopy, endoscopy, and postendoscopy assessments, and the last session commented on the particular scenario of an overview of UGIB from the Taiwan NHIRD. Based on the review of the literature, the draft statements of the consensus were established by the session leader(s) of each scope session. For each statement, the level of evidence was defined according to modified grading of the Oxford Centre for Evidence-Based Medicine Levels of Evidence (March, 2009) [7]. The draft statements were refined at the steering committee meeting held in Tainan during May 2013.

2.3. Expert Group Process to Achieve Agreement of Statement and Grading of Recommendation. The expert group of the Taiwan UGIB consensus comprised a total of 32 experts, including 10 members in the steering committee and 22 members who accepted the invitation of the steering committee. The draft statements from the four session groups were sent to all experts, together with pertinent literature before the consensus meeting in Taichung in July 2013.

During the two-day consensus meeting, for each draft statement from the four scope sessions, the supporting evidence from the keynote literature summary by the steering committee was presented serially in order from preendoscopy, endoscopy, and postendoscopy to NHIRD assessments. Based on a modified Delphi process through two separate iterations, all participants voted anonymously for the first round of statements and modified the statements by discussion. The modified statements were followed by a second round of voting with electronic keypads until a consensus was reached at the agreement percentage of ≥80%. If the agreement was less than 80%, the statement was rejected.

The expert members also discussed the level of evidence suggested by the steering committee and then provided grading of the recommendation level by voting for each statement. The grading of recommendation into 4 grades from A to D was applied as in the Asia-Pacific working group consensus for UGIB [2]. The level of recommendation was defined as the grade with the highest number of votes of the expert group members. The conferences were underwritten by unrestricted grants from the Gastroenterological Society of Taiwan. Mandatory written disclosures of financial conflict of interests within the period of three years before the meetings were obtained from all experts before voting.

3. Consensus Statements

3.1. Section I: Preendoscopy Assessment

Statement I-1. For specific comorbid patients with uremia or coronary artery diseases, to raise hematocrit at least >30% shall be beneficial (agreement: 94%, level of evidence: 1b, and recommendation: A).

For patients who present with acute bleeding, hemoglobin (Hb) concentration < 7 g/dL is an indication for blood transfusion. For those with Hb concentration > 10 g/dL, blood transfusion is rarely indicated [1]. Among patients with bleeding from a peptic ulcer, further bleeding risk is lower in the strategy with threshold transfusion of Hb < 7 g/dL than in the strategy with Hb < 9 g/dL [8].

Special consideration should be given for blood transfusions in UGIB patients with comorbid diseases including uremia and acute myocardial infarction to keep the hematocrit level above 30% [9, 10]. The platelet-mediated hemorrhagic
tendency in uremia may be managed successfully by raising hemocrit to above 30% [11].

Statement I-2. The pre-endoscopy Rockall score is a useful tool to identify high-risk patients who need further endoscopic therapy and radiologic and surgical interventions (agreement: 90%, level of evidence: 2b, and recommendation: B).

Rockall scoring system combining both clinical and endoscopic variables may identify patients who are given early discharge or outpatient management who are in need of more aggressive treatment interventions, including endoscopy, and who have further bleeding or death [12]. In predicting the need for endoscopic therapy, the Glasgow-Blatchford score may be more useful in detecting which patients need clinical intervention than the preendoscopic Rockall score [13, 14]. However, only 1% to 5% of cohort cases have Glasgow-Blatchford score of 0 to indicate that they are at low risk and intervention is not required [14, 15]. So the expert discussions preserve the statement to be more focused on Rockall score and suggest there should be a need of local validations for the Glasgow-Blatchford score in future.

Statement I-3. Preendoscopic intravenous proton pump inhibitor can enhance resolution of stigmata of bleeding and decrease the need of endoscopic therapy, though it cannot replace the urgent endoscopy (agreement: 97%, level of evidence: 1a, and recommendation: A).

The use of intravenous proton pump inhibitors (PPI) before endoscopy can reduce endoscopic therapy at index endoscopy, but it does not improve the clinical outcome of UGIB including rebleeding, surgery, or mortality [16, 17]. Nevertheless, endoscopy should generally be conducted within 24 hours for UGIB [18, 19], and the preendoscopic administration of PPI should not delay or replace urgent endoscopy for UGIB.

3.2. Section II: Endoscopy Assessment

Statement II-1. Stigmata of recent hemorrhage (SRH) of bleeding peptic ulcer can predict the risk of rebleeding and guide management decisions. Forrest classification is commonly used to describe SRH (agreement: 100%, level of evidence: 2b, and recommendation: A).

The stigmata of recent hemorrhage (SRH) are now widely used to record the endoscopic finding of bleeding peptic ulcers with the classification of Forrest et al., to disclose recurrent bleeding rates [20, 21], and to guide endoscopic hemostasis [22–25] and time to discharge [26–28]. For example, a visible vessel has average 43% rebleeding risk [21], needs endoscopic hemostatic therapies [24], and takes four days to disappear [26].

Statement II-2. Endoscopic therapy is recommended to be provided for patients with high-risk lesions, such as active spurting, oozing bleeding, or a nonbleeding visible vessel (Forrest Ia, Ib, or Ila) (agreement: 100%, level of evidence: 1a, and recommendation: A).

Meta-analyses of randomized controlled trials confirmed the benefits of endoscopic hemostatic therapies to arrest active bleeding or decrease recurrent bleeding for high-risk bleeding peptic ulcers (such as Forrest Ia, Ib, or Ila lesions) [22–25]. Endoscopic hemostatic therapies including injection, thermal therapy, and a combination are better than pharmacotherapy only to control peptic ulcer recurrent bleeding [24, 25].

Statement II-3. Endoscopic therapy may be considered for ulcers with adherent clots (Forrest IIb) (agreement: 100%, level of evidence: 1a, and recommendation: A).

A meta-analysis suggested that endoscopic therapy is superior to medical therapy and to decrease recurrent bleeding and surgery but without improvement in mortality [29]. However, another meta-analysis did not show significant benefit in any clinical outcomes [24]. Because these studies had the variable definition of adherent clots and different results, what to do with clots remains inconclusive.

Statement II-4. Endoscopic therapy is not routinely recommended to ulcers with a flat pigmented spot or a clean base (Forrest IIc or III) (agreement: 93%, level of evidence: 2b, and recommendation: A).

The rates of recurrent bleeding may be as low as 5%–10% in bleeding ulcers with a clean base and flat pigmented spot without endoscopic therapy [21], and they are thus not in need of endoscopic therapy.

Statement II-5. Epinephrine injection therapy is recommended to be combined with a second modality (agreement: 90%, level of evidence: 1a, and recommendation: A).

Endoscopic injection of epinephrine is less effective than other monotherapies to prevent recurrent ulcer bleeding [24, 25]. By combining epinephrine injections with a second modality (such as thermal coagulation, fibrin glue, or hemoclip), the outcome of UGIB, including further bleeding and the need for surgery, may be much improved [22–25, 30].

3.3. Section III: Postendoscopy Assessment

Statement III-1. Patients with bleeding peptic ulcers are recommended to be treated with intravenous high dose or nonhigh dose of proton pump inhibitors, as bolus or continuous infusion for 72 hours after successful endoscopic therapy (agreement: 97%, level of evidence: 1a, and recommendation: A).

An intravenous PPI administration can improve control of peptic ulcer bleeding after endoscopic therapy [31, 32]. A nonhigh dose regimen can still be as efficacious as a high dose regimen of PPI (such as esomeprazole at least 8 mg/hr intravenous infusion for 72 hr) to control recurrent peptic ulcer bleeding [32–34]. Nevertheless, a recent Cochrane review showed that low quality evidence did not exclude either a potential reduction or an increase in outcomes including rebleeding, surgery, mortality, and repeated endoscopic hemostatic treatment, with high dose compared to nonhigh dose proton pump inhibitor regimens [35].

Statement III-2. Oral proton pump inhibitors could be an alternative treatment to intravenous infusion after successful
endoscopic hemostasis for low-risk peptic ulcer bleeding (agreement: 87%, level of evidence: Ib, and recommendation: B).

The hospital stay, need for blood transfusion, recurrent bleeding, and mortality are similar for oral high dose PPI and intravenous PPI infusion after endoscopic hemostasis among low-risk patients, whose Rockall scores <6 or American Society of Anesthesiologists class I or II [36, 37].

Statement III-3. For NSAID users with previous peptic ulcer bleeding, either nonselective NSAID to plus PPI or COX-2 inhibitor alone can reduce the recurrent peptic bleeding. Otherwise, COX-2 inhibitor plus PPI may offer better gastro-duodenal protection (agreement: 97%, level of evidence: Ib, and recommendation: A).

For the users of nonsteroid anti-inflammatory drugs (NSAIDs) with a previous history of peptic ulcer bleeding, either a cyclooxygenase-2 (COX-2) inhibitor or a nonselective NSAID plus PPI can reduce the recurrent bleeding [38]. The combination of a COX-2 inhibitor and PPI can achieve nearly no recurrence rate of peptic ulcer bleeding [39].

Statement III-4. Patients with comorbidities or poor nutrition status have higher incidence of peptic ulcer diseases and recurrent bleeding (agreement: 100%, level of evidence: 2b, and recommendation: B).

Nosocomial bleeding [40] and the presence of comorbidities [12, 41] including uremia [34, 42, 43], liver cirrhosis [41, 44], chronic obstructive pulmonary disease [34], and poor nutrition status as hypoalbuminemia [45] are the significant factors to have a higher incidence of peptic ulcer disease or recurrent bleeding. The domestic data suggested the effect of 3-day PPI infusion after therapeutic endoscopy was limited to prevent recurrence bleeding in patients with comorbidities [45, 46]. Extending the duration of intravenous PPI infusion to 7 days or doubling the dose of oral PPI as twice daily after 3-day intravenous infusion can improve the control of recurrent bleeding in such high-risk populations [47, 48]. This implies that more aggressive acid control is necessary for high-risk patients who are defined by Rockall score ≥6 [48].

Statement III-5. In bleeding ulcer patients who require low-dose aspirin therapy for cardiovascular prophylaxis, aspirin plus PPI should be restarted as soon as possible, once hemostasis can be achieved or cardiovascular risks outweigh gastrointestinal risks (agreement: 97%, level of evidence: Ib, and recommendation: A).

It is reasonable to stop the antiplatelet therapy during acute ulcer bleeding [49]. Once hemostasis is achieved, early resumption of antiplatelet agents with PPI at 3-5 days after the last dose can be suitable [50, 51]. For the long-term prevention of peptic ulcer bleeding, cotherapy with PPI is suggested for aspirin or clopidogrel users [52–55]. The COGENT trial confirmed a reduction in gastrointestinal bleeding risk without increase in cardiovascular events when clopidogrel was coprescribed with omeprazole [56].

Statement III-6. The second-look endoscopy is not routine for all patients but can be reserved for the high-risk patients (agreement: 100%, level of evidence: 1a, and recommendation: B).

There are no proven benefits by second-look endoscopy and, considering the availability of high dose PPIs, the second-look endoscopy may be reserved for high-risk patients [57, 58]. A meta-analysis showed that routine second-look endoscopy in peptic ulcer bleeding might be effective in high-risk patients, including those with hemodynamic instability, active bleeding, large ulcers, ulcer of posterior wall of bulb, and more or active comorbidities [1, 58]. Therefore, there is a pressing need for further studies to elucidate the role and, moreover, the selection criteria of second-look endoscopy. This is the reason why the expert members had 100% agreement but only B recommendation.

3.4. Section IV: Special Scenario of an Overview of UGIB from the NHIRD

Statement IV-1. Taiwan NHIRD researches identify the high-risk populations of peptic ulcer bleeding and recurrent bleeding, including liver cirrhosis, end stage renal disease, probably chronic obstructive pulmonary disease, and type II diabetes (agreement: 100%, level of evidence: 2b, and recommendation: B).

A number of nationwide studies using the NHIRD in Taiwan have identified several populations at risk of peptic ulcer bleeding, including those with liver cirrhosis, end stage renal disease, type II diabetes, chronic obstructive pulmonary disease, age > 65 years, male gender, hypertension, heart failure, history of peptic ulcer disease, and chronic users of NSAIDs [59–63]. These underlying comorbidities may serve as independent risk factors of the recurrent ulcer bleeding [46, 64, 65]. The effect of life-long antisecretory medications in prevention of peptic ulcer recurrence in high-risk populations represents an important topic for future research.

Statement IV-2. Taiwan NHIRD researches identify NSAID and high-affinity serotonin reuptake inhibitors increase the risk of peptic ulcer bleeding (agreement: 97%, level of evidence: 3b, and recommendation: B).

The nonselective NSAIDs are significantly associated with a higher risk of UGIB [66, 67]. Selective serotonin reuptake inhibitors also predispose to recurrent bleeding of UGIB [68, 69]. Concomitant use of antisecretory medications may therefore be suggested.

Statement IV-3. Taiwan NHIRD researches support the fact that H. pylori eradication reduces peptic ulcer diseases and the risk of gastric cancer for patients with peptic ulcer diseases (agreement: 90%, level of evidence: 2b, and recommendation: B).

Anti-H. pylori therapy given within 6 months of ulcer diagnosis can reduce the ulcer events [70, 71] and prevent bleeding recurrence [72]. An increased risk of gastric cancer correlates with a late eradication beyond one year in patients with peptic ulcer. Early H. pylori eradication is therefore suggested as an independent protective factor to reduce the risk of gastric cancer [73]. This result is compatible with a large-scale study and meta-analysis, showing that eradication
of *H. pylori* decreases the development of gastric cancer only among those without precancerous lesion [74, 75].

### 4. Dissemination Strategies and Legal Issues

These statements are based on the best available evidence to pursue better quality of care and will be updated per 5 years. They are not suitable for deciding standard of care in specific cases. This consensus statement will be disseminated by (1) presentations given at the annual society meeting of Taiwan Digestive Week in 2013; (2) possible release of copies of these statements in electronic and paper format to national societies/associations of gastroenterologists for their iterations; (3) release on the website of our society link.

### Abbreviations

- COX-2: Cyclooxygenase-2
- NHIRD: National Health Insurance Research Database
- NSAIDs: Nonsteroid anti-inflammatory drugs
- NTT: Number needed for treatment
- PPI: Proton pump inhibitor
- RR: Relative risk
- SRH: Stigmata of recent hemorrhage
- UGIB: Upper gastrointestinal bleeding.

### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

### Authors’ Contribution

Bor-Shyang Sheu and Chun-Ying Wu contributed equally to this study. Dr. B. S. Sheu coordinated as the chairman of the Taiwan expert group to compose the draft of the paper. Dr. C. Y. Wu served as the cochairman and Drs. M. S. Wu, C. T. Chiu, C. C. Lin, P. I. Hsu, H. C. Cheng, T. Y. Lee, and H. P. Wang reviewed the literatures and statements. Dr. J. T. Lin applied the funding for the expert meeting and critically reviewed the paper.

### Acknowledgments

This work was supported by voting of the statements by the Taiwan expert groups, with names listed in the supplemental file. The authors received funding from the Gastroenterological Society of Taiwan. Provenance and peer review were not commissioned as the paper was externally peer reviewed. The expert consensus was conducted by experts including the following gastroenterologists: Dr. Wen-Hsiung Chang, Mackay Memorial Hospital, Taipei; Dr. Chia-Long Lee, Hsinchu Cathay General Hospital, Hsinchu; Dr. Chun-Jung Lin, Chang Gung Memorial Hospital, Linko; Dr. Jyh-Ming Liou, National Taiwan University Hospital, Taipei; Dr. Ming-Jen Sheu, Chi Mei Medical Center, Tainan; Dr. Deng-Chyang Wu and Dr. Jeng-Yih Wu, Kaohsiung Medical University Hospital, Kaohsiung; Dr. Jiann-Hwa Chen, Taipei Tzu Chi Hospital, Taipei; Dr. Kuan-Yang Chen, Ren-Ai Branch, Taipei City Hospital, Taipei; Dr. Yang-Yuan Chen, China Medical University Hospital, Taichung; Dr. Chao-Sheng Liao, Shin Kong Wu Ho-Su Memorial Hospital, Taipei; Dr. Hsu-Heng Yen, Changhua Christian Hospital, Changhua; Dr. Chien-Hua Chen, Show Chwan Memorial Hospital, Changhua; Dr. Ming-Chih Hou and Dr. Ji-Ying-Chyuan Luo, Taipei Veterans General Hospital, Taipei; Dr. Ming-Jong Bair, Taichung Branch, Mackay Memorial Hospital, Taichung; Dr. Chi-Yang Chang and Dr. Wen-Lun Wang, E-Da Hospital, Kaohsiung; Dr. Chun-Chao Chang, Taipei Medical University Hospital, Taipei; Dr. Wei-Kuo Chang, Tri-Service General Hospital, Taipei; and Dr. Chi-Tan Hu, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.

### References

[1] A. N. Barkun, M. Bardou, E. J. Kuipers et al., “International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding,” *Annals of Internal Medicine*, vol. 152, no. 2, pp. 101–113, 2010.

[2] J. Y. Y. Sung, F. K. L. Chan, M. Chen et al., “Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding,” *Gut*, vol. 60, no. 9, pp. 1170–1177, 2011.

[3] A. Barkun, S. Sabbah, R. Enns et al., “The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting,” *The American Journal of Gastroenterology*, vol. 99, no. 7, pp. 1238–1246, 2004.

[4] K. Bensoussan, C. A. Fallone, A. N. Barkun et al., “A sampling of Canadian practices in managing nonvariceal upper gastrointestinal bleeding before recent guideline publication: is there room for improvement?” *Canadian Journal of Gastroenterology*, vol. 19, no. 8, pp. 487–495, 2005.

[5] J. Y. W. Lau, A. Barkun, D. Fan, E. J. Kuipers, Y. Yang, and F. K. L. Chan, “Challenges in the management of acute peptic ulcer bleeding,” *The Lancet*, vol. 381, no. 9882, pp. 2033–2043, 2013.

[6] D. K. L. Chow and J. Y. Y. Sung, “Non-NSAID non-*H. pylori* ulcer disease,” *Best Practice and Research: Clinical Gastroenterology*, vol. 23, no. 1, pp. 3–9, 2009.

[7] OCEBM Levels of Evidence Working Group, *The Oxford Levels of Evidence 1*, Oxford Centre for Evidence-Based Medicine, 2014, http://www.cebm.net/index.aspx?o=1025.

[8] C. Villanueva, A. Colomo, A. Bosch et al., “Transfusion strategies for acute upper gastrointestinal bleeding,” *The New England Journal of Medicine*, vol. 368, no. 1, pp. 11–21, 2013.

[9] S. J. Hedges, S. B. Dehoney, J. S. Hooper, I. Amanzadeh, and A. J. Bux, “Evidence-based treatment recommendations for uremic bleeding,” *Nature Clinical Practice Nephrology*, vol. 3, no. 3, pp. 138–153, 2007.

[10] W. C. Wu, S. S. Rathore, Y. Wang, M. J. Radford, and H. M. Krumholz, “Blood transfusion in elderly patients with acute myocardial infarction,” *New England Journal of Medicine*, vol. 345, no. 17, pp. 1230–1236, 2001.

[11] M. Livio, E. Gotti, D. Marchesi, G. Mecca, G. Remuzzi, and G. de Gaetano, “Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions,” *The Lancet*, vol. 2, no. 8306, pp. 1013–1015, 1982.
[12] T. A. Rockall, R. F. A. Logan, H. B. Devlin, and T. C. Northfield, “Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage,” The Lancet, vol. 347, no. 9009, pp. 1138–1140, 1996.

[13] O. Blatchford, W. R. Murray, and M. Blatchford, “A risk score to predict need for treatment for upper-gastrointestinal haemorrhage,” The Lancet, vol. 356, no. 9238, pp. 1318–1321, 2000.

[14] C. H. Wang, Y. W. Chen, Y. R. Young, C. J. Yang, and I. C. Chen, “A prospective comparison of 3 scoring systems in upper gastrointestinal bleeding,” The American Journal of Emergency Medicine, vol. 31, no. 5, pp. 775–778, 2013.

[15] A. O. Lo and J. Y. Lau, “Gastrointestinal bleeding,” Endoscopy, vol. 46, pp. 310–313, 2014.

[16] J. Y. Lau, W. K. Leung, J. C. Y. Wu et al., “Omeprazole before endoscopy in patients with gastrointestinal bleeding,” The New England Journal of Medicine, vol. 356, no. 16, pp. 1631–1640, 2007.

[17] A. Sreedharan, J. Martin, G. I. Leontiadis et al., “Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (review),” Cochrane Database of Systematic Reviews, vol. 7, Article ID CD004510, 2010.

[18] H. J. Lin, K. Wang, C. L. Perng et al., “Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective randomized study,” Journal of Clinical Gastroenterology, vol. 22, no. 4, pp. 267–271, 1996.

[19] C. M. Tai, S. P. Huang, H. P. Wang et al., “High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage undergoing emergency or urgent endoscopy: a retrospective analysis,” The American Journal of Emergency Medicine, vol. 25, no. 3, pp. 273–278, 2007.

[20] J. A. H. Forrest, N. D. C. Finlayson, and D. J. C. Shearman, “Endoscopy in gastrointestinal bleeding,” The Lancet, vol. 2, no. 7877, pp. 394–397, 1974.

[21] L. Laine and W. L. Peterson, “Bleeding peptic ulcer,” The New England Journal of Medicine, vol. 331, no. 11, pp. 717–727, 1994.

[22] X. Calvet, M. Vergara, E. Brullet, J. P. Gisbert, and R. Campo, “Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers,” Gastroenterology, vol. 126, no. 2, pp. 441–450, 2004.

[23] R. Marmo, G. Rotondaro, R. Piscopo, M. A. Bianco, R. D’Angelica, and L. Cipolletta, “Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials,” The American Journal of Gastroenterology, vol. 102, no. 2, pp. 279–289, 2007.

[24] L. Laine and K. R. McQuaid, “Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials,” Clinical Gastroenterology and Hepatology, vol. 7, no. 1, pp. 33–47, 2009.

[25] A. N. Barkun, M. Martel, Y. Toubouti, E. Rahme, and M. Bardou, “Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses,” Gastrointestinal Endoscopy, vol. 69, no. 4, pp. 786–799, 2009.

[26] C.-C. Yang, J.-S. Shin, X.-Z. Lin, P.-I. Hsu, K.-W. Chen, and C.-Y. Lin, “The natural history (fading time) of stigmata of recent hemorrhage in peptic ulcer disease,” Gastrointestinal Endoscopy, vol. 40, no. 5, pp. 562–566, 1994.

[27] P. Hsu, X. Lin, S. Chan et al., “Bleeding peptic ulcer—risk factors for rebleeding and sequential changes in endoscopic findings,” Gut, vol. 35, no. 6, pp. 746–749, 1994.

[28] P. I. Hsu, K. H. Lai, X. Z. Lin et al., “When to discharge patients with bleeding peptic ulcers: a prospective study of residual risk of rebleeding,” Gastrointestinal Endoscopy, vol. 44, no. 4, pp. 382–387, 1996.

[29] C. J. Kahi, D. M. Jensen, J. J. Y. Sung et al., “Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis,” Gastroenterology, vol. 129, no. 3, pp. 855–862, 2005.

[30] C. C. Lo, P. I. Hsu, G. H. Lo et al., “Comparison of hemostatic efficacy for epinephrine injection alone and injection combined with hemoclip therapy in treating high-risk bleeding ulcers,” Gastrointestinal Endoscopy, vol. 63, no. 6, pp. 767–773, 2006.

[31] H. Lin, W. Lo, F. Lee, C. Pergn, and G. Tseng, “A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy,” Archives of Internal Medicine, vol. 158, no. 1, pp. 54–58, 1998.

[32] J. I. Sung, A. Barkun, E. J. Kuipers et al., “Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding,” Annals of Internal Medicine, vol. 150, no. 7, pp. 455–464, 2009.

[33] C. Wang, M. H. Ma, H. Chou et al., “High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials,” Archives of Internal Medicine, vol. 170, no. 9, pp. 751–758, 2010.

[34] C.-C. Chen, J.-Y. Lee, Y.-J. Fang et al., “Randomised clinical trial: high-dose vs standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 8, pp. 894–903, 2012.

[35] I. Neumann, L. M. Letelier, G. Rada et al., “Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding,” Cochrane Database of Systematic Reviews, vol. 6, Article ID CD007999, 2013.

[36] H. Yen, C. Yang, W. Su, M. Soon, S. Wu, and H. Lin, “Oral versus intravenous proton pump inhibitors in preventing rebleeding for patients with peptic ulcer bleeding after successful endoscopic therapy,” BMC Gastroenterology, vol. 12, article 66, 2012.

[37] J. J. Sung, B. Y. Suen, J. C. Wu, J. Y. Lau, J. Y. Ching, and V. W. Lee, “Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy,” The American Journal of Gastroenterology, vol. 109, no. 7, pp. 1005–1010, 2014.

[38] F. K. L. Chan, L. C. T. Hung, B. Y. Suen et al., “Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial,” Gastroenterology, vol. 127, no. 4, pp. 1038–1043, 2004.

[39] F. K. L. Chan, V. W. S. Wong, B. Y. Suen et al., “Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial,” The Lancet, vol. 369, no. 9573, pp. 1621–1626, 2007.

[40] N. J. Liu, C. S. Lee, J. H. Tang et al., “Outcomes of bleeding peptic ulcers: a prospective study,” Journal of Gastroenterology and Hepatology, vol. 23, no. 8, pp. e340–e347, 2008.

[41] A. M. Zaragoza, J. M. Tenías, M. J. Llorente, and A. Alborch, “Prognostic factors in gastrointestinal bleeding due to peptic ulcer: construction of a predictive model,” Journal of Clinical Gastroenterology, vol. 42, no. 7, pp. 786–790, 2008.
[42] G.-Y. Tseng, C.-T. Fang, H.-J. Lin et al., “Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with varices: a case-control study,” *Alimentary Pharmacology and Therapeutics*, vol. 30, no. 4, pp. 406–413, 2009.

[43] S.-C. Lin, K.-L. Wu, K.-W. Chiu et al., “Risk factors influencing the outcome of peptic ulcer bleeding in end stage renal diseases after initial endoscopic haemostasis,” *International Journal of Clinical Practice*, vol. 66, no. 8, pp. 774–781, 2012.

[44] L. Chen, H. Lin, S. Hwang, F. Lee, M. Hou, and S. Lee, “Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension,” *Journal of Gastroenterology and Hepatology*, vol. 11, no. 1, pp. 59–64, 1996.

[45] H. C. Cheng, A. W. Kao, C. H. Chuang, and B. S. Sheu, “The efficacy of high- and low-dose intravenous omeprazole in preventing rebleeding for patients with bleeding peptic ulcers and comorbid illnesses,” *Digestive Diseases and Sciences*, vol. 50, no. 7, pp. 1194–1201, 2005.

[46] H. Cheng, S. Chuang, Y. Kao, A. Kao, C. Chuang, and B. Sheu, “Increased risk of rebleeding of peptic ulcer bleeding in patients with comorbid illness receiving omeprazole infusion,” *Hepato-Gastroenterology*, vol. 50, no. 54, pp. 2270–2273, 2003.

[47] H. C. Cheng, W. L. Chang, Y. C. Yeh, W. Y. Chen, Y. C. Tsai, and B. S. Sheu, “Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities,” *Gastrointestinal Endoscopy*, vol. 70, no. 3, pp. 433–439, 2009.

[48] H. C. Cheng, C. T. Wu, W. L. Chang, W. C. Cheng, W. Y. Chen, and B. S. Sheu, “Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study,” *Gut*, 2014.

[49] T. Komatsu, Y. Tamai, H. Takami, K. Yamagata, S. Fukuda, and A. Munakata, “Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures,” *Journal of Gastroenterology*, vol. 40, no. 7, pp. 698–707, 2005.

[50] J. J. Y. Sung, J. Y. W. Lau, J. Y. L. Ching et al., “Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial,” *Annals of Internal Medicine*, vol. 152, no. 1, pp. 1–9, 2010.

[51] P. Hsu, “New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment,” *Journal of Gastroenterology and Hepatology*, vol. 27, no. 4, pp. 654–661, 2012.

[52] C. P. Liu, W. C. Chen, K. H. Lai et al., “Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers,” *American Journal of Gastroenterology*, vol. 107, no. 7, pp. 1022–1029, 2012.

[53] K. C. Lai, K. M. Chu, W. M. Hui et al., “Esomeprazole versus aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications,” *Clinical Gastroenterology and Hepatology*, vol. 4, no. 7, pp. 860–865, 2006.

[54] P. I. Hsu, K. H. Lai, and C. P. Liu, “Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis,” *Gastroenterology*, vol. 140, no. 3, pp. 791–798, 2011.

[55] F. K. L. Chan, J. Y. L. Ching, and L. C. T. Hung, “Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding,” *The New England Journal of Medicine*, vol. 352, no. 3, pp. 317–319, 2005.

[56] D. L. Bhatt, B. L. Cryer, C. F. Contant et al., “Clopidogrel with or without omeprazole in coronary artery disease,” *The New England Journal of Medicine*, vol. 363, no. 20, pp. 1909–1917, 2010.

[57] K. K. F. Tsoi, H. C. H. Chan, P. W. Y. Chiu, C. Y. Y. Pau, J. Y. W. Lau, and J. Y. Y. Sung, “Second-look endoscopy with thermal coagulation or injections for peptic ulcer bleeding: a meta-analysis,” *Journal of Gastroenterology and Hepatology*, vol. 25, no. 1, pp. 8–13, 2010.

[58] S. E. Ouali, A. N. Barkun, J. Wyse et al., “Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis,” *Gastrointestinal Endoscopy*, vol. 76, no. 2, pp. 283–292, 2012.

[59] J.-C. Luo, H.-B. Leu, M.-C. Hou et al., “Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study,” *Alimentary Pharmacology and Therapeutics*, vol. 36, no. 6, pp. 542–550, 2012.

[60] C. C. Kuo, H. W. Kuo, I. M. Lee, C. T. Lee, and C. Y. Yang, “The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study,” *BMC Nephrology*, vol. 14, article 15, 2013.

[61] J. Luo, H. Leu, K. Huang et al., “Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis,” *Canadian Medical Association Journal*, vol. 183, no. 18, pp. E1345–E1351, 2011.

[62] Y. L. Peng, H. B. Leu, J. C. Luo et al., “Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study,” *Journal of Gastroenterology and Hepatology*, vol. 28, no. 8, pp. 1295–1299, 2013.

[63] K. W. Huang, J. C. Luo, H. B. Leu et al., “Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study,” *Alimentary Pharmacology and Therapeutics*, vol. 35, no. 7, pp. 796–802, 2012.

[64] C. Wu, M. Wu, K. N. Kuo, C. Wang, Y. Chen, and J. Lin, “Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study,” *Gut*, vol. 60, no. 8, pp. 1038–1042, 2011.

[65] Y. C. Hsu, J. T. Lin, T. T. Chen, M. S. Wu, and C. Y. Wu, “Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study,” *Hepatology*, vol. 56, no. 2, pp. 698–705, 2012.

[66] C. H. Chang, H. C. Chen, J. W. Lin, C. W. Kuo, W. Y. Shau, and M. S. Lai, “Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan,” *Pharmacoepidemiology and Drug Safety*, vol. 20, no. 7, pp. 763–771, 2011.

[67] Y. Lee, C. Chang, J. Lin, H. Chen, M. Lin, and M. Lai, “Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients,” *Liver International*, vol. 32, no. 5, pp. 859–866, 2012.

[68] N. Li, N. H. Wallen, M. Ladjevardi, and P. Hjemdahl, “Effects of serotonin on platelet activation in whole blood,” *Blood Coagulation and Fibrinolysis*, vol. 8, no. 8, pp. 517–523, 1997.

[69] Y. C. Lee, W. Y. Shau, C. H. Chang, S. T. Chen, M. S. Lin, and M. S. Lai, “Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients: a nationwide cohort study in Taiwan,” *Journal of Clinical Psychopharmacology*, vol. 32, no. 4, pp. 518–524, 2012.

[70] C. Wu, M. Wu, C. Wang, J. Cheng, K. N. Kuo, and J. Lin, “A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with *H. pylori* eradication and proton pump inhibitor use,” *Clinical Gastroenterology and Hepatology*, vol. 7, no. 4, pp. 427–431, 2009.

[71] F. Hsiao, Y. Tsai, Y. Wen, K. N. Kuo, C. Tsai, and W. Huang, “Effect of *Helicobacter pylori* eradication therapy on risk of...
hospitalization for a major ulcer event," *Pharmacotherapy*, vol. 31, no. 3, pp. 239–247, 2011.

[72] J. P. Gisbert, S. Khorrami, F. Carballo, X. Calvet, E. Gené, and J. E. Dominguez-Muñoz, "*H. pylori* eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer," *Cochrane Database of Systematic Reviews*, no. 2, Article ID CD004062, 2004.

[73] C. Wu, K. N. Kuo, M. Wu, Y. Chen, C. Wang, and J. Lin, "Early *Helicobacter pylori* eradication decreases risk of gastric cancer in patients with peptic ulcer disease," *Gastroenterology*, vol. 137, no. 5, pp. 1641–1648, 2009.

[74] B. C. Wong, S. K. Lam, W. M. Wong et al., "*Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China, a randomized controlled trial," *The Journal of the American Medical Association*, vol. 291, no. 2, pp. 187–194, 2004.

[75] L. Fuccio, R. M. Zagari, L. H. Eusebi, L. Laterza, V. Cennamo, and L. Ceroni, "Meta-analysis: can *Helicobacter pylori* eradication treatment reduce the risk for gastric cancer?" *Annals of Internal Medicine*, vol. 151, no. 2, pp. 121–128, 2009.